These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
283 related articles for article (PubMed ID: 32294191)
1. Pretreatment Endocrine Disorders Due to Optic Pathway Gliomas in Pediatric Neurofibromatosis Type 1: Multicenter Study. Santoro C; Perrotta S; Picariello S; Scilipoti M; Cirillo M; Quaglietta L; Cinalli G; Cioffi D; Di Iorgi N; Maghnie M; Gallizia A; Parpagnoli M; Messa F; De Sanctis L; Vannelli S; Marzuillo P; Miraglia Del Giudice E; Grandone A J Clin Endocrinol Metab; 2020 Jun; 105(6):. PubMed ID: 32294191 [TBL] [Abstract][Full Text] [Related]
2. Optic pathway glioma and endocrine disorders in patients with and without NF1. Gil Margolis M; Yackobovitz-Gavan M; Toledano H; Tenenbaum A; Cohen R; Phillip M; Shalitin S Pediatr Res; 2023 Jan; 93(1):233-241. PubMed ID: 35538247 [TBL] [Abstract][Full Text] [Related]
3. Endocrine Long-Term Follow-Up of Children with Neurofibromatosis Type 1 and Optic Pathway Glioma . Sani I; Albanese A Horm Res Paediatr; 2017; 87(3):179-188. PubMed ID: 28346917 [TBL] [Abstract][Full Text] [Related]
4. Optic pathway gliomas in patients with neurofibromatosis type 1: follow-up of 44 patients. Segal L; Darvish-Zargar M; Dilenge ME; Ortenberg J; Polomeno RC J AAPOS; 2010 Apr; 14(2):155-8. PubMed ID: 20451859 [TBL] [Abstract][Full Text] [Related]
5. Brain gliomas, hydrocephalus and idiopathic aqueduct stenosis in children with neurofibromatosis type 1. Glombova M; Petrak B; Lisy J; Zamecnik J; Sumerauer D; Liby P Brain Dev; 2019 Sep; 41(8):678-690. PubMed ID: 31000370 [TBL] [Abstract][Full Text] [Related]
6. Visual acuity of children treated with chemotherapy for optic pathway gliomas. Kalin-Hajdu E; Décarie JC; Marzouki M; Carret AS; Ospina LH Pediatr Blood Cancer; 2014 Feb; 61(2):223-7. PubMed ID: 23956233 [TBL] [Abstract][Full Text] [Related]
7. Growth hormone excess in children with neurofibromatosis type-1 and optic glioma. Cambiaso P; Galassi S; Palmiero M; Mastronuzzi A; Del Bufalo F; Capolino R; Cacchione A; Buonuomo PS; Gonfiantini MV; Bartuli A; Cappa M; Macchiaiolo M Am J Med Genet A; 2017 Sep; 173(9):2353-2358. PubMed ID: 28631895 [TBL] [Abstract][Full Text] [Related]
8. Serial MRIs provide novel insight into natural history of optic pathway gliomas in patients with neurofibromatosis 1. Sellmer L; Farschtschi S; Marangoni M; Heran MKS; Birch P; Wenzel R; Mautner VF; Friedman JM Orphanet J Rare Dis; 2018 Apr; 13(1):62. PubMed ID: 29685181 [TBL] [Abstract][Full Text] [Related]
9. Neurofibromatosis type 1-associated optic pathway gliomas: pathogenesis and emerging treatments. Amato A; Imbimbo BP; Falsini B Eur Rev Med Pharmacol Sci; 2023 Jun; 27(12):5636-5653. PubMed ID: 37401302 [TBL] [Abstract][Full Text] [Related]
10. Precocious and accelerated puberty in children with neurofibromatosis type 1: results from a close follow-up of a cohort of 45 patients. Pinheiro SL; Maciel J; Cavaco D; Figueiredo AA; Damásio IL; Donato S; Passos J; Simões-Pereira J Hormones (Athens); 2023 Mar; 22(1):79-85. PubMed ID: 36269545 [TBL] [Abstract][Full Text] [Related]
12. Fractional anisotropy of the optic radiations is associated with visual acuity loss in optic pathway gliomas of neurofibromatosis type 1. de Blank PM; Berman JI; Liu GT; Roberts TP; Fisher MJ Neuro Oncol; 2013 Aug; 15(8):1088-95. PubMed ID: 23658320 [TBL] [Abstract][Full Text] [Related]
13. Neurofibromatosis type 1 and optic pathway gliomas: follow-up of 54 patients. Thiagalingam S; Flaherty M; Billson F; North K Ophthalmology; 2004 Mar; 111(3):568-77. PubMed ID: 15019338 [TBL] [Abstract][Full Text] [Related]
14. The Use of Magnetic Resonance Imaging Screening for Optic Pathway Gliomas in Children with Neurofibromatosis Type 1. Prada CE; Hufnagel RB; Hummel TR; Lovell AM; Hopkin RJ; Saal HM; Schorry EK J Pediatr; 2015 Oct; 167(4):851-856.e1. PubMed ID: 26233602 [TBL] [Abstract][Full Text] [Related]
15. Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis. Fisher MJ; Loguidice M; Gutmann DH; Listernick R; Ferner RE; Ullrich NJ; Packer RJ; Tabori U; Hoffman RO; Ardern-Holmes SL; Hummel TR; Hargrave DR; Bouffet E; Charrow J; Bilaniuk LT; Balcer LJ; Liu GT Neuro Oncol; 2012 Jun; 14(6):790-7. PubMed ID: 22474213 [TBL] [Abstract][Full Text] [Related]
16. Clinical Presentation and Outcome of Patients With Optic Pathway Glioma. Robert-Boire V; Rosca L; Samson Y; Ospina LH; Perreault S Pediatr Neurol; 2017 Oct; 75():55-60. PubMed ID: 28847625 [TBL] [Abstract][Full Text] [Related]